NEW YORK (GenomeWeb) – Myriad Genetics reported after the close of the market Tuesday that its first quarter revenues for fiscal year 2015 declined 17 percent year over year.

For the three months ended Sept. 30, the Salt Lake City-based molecular diagnostics firm had total revenues of $168.8 million, compared to revenues of $202.5 million in fiscal Q1 2014. The revenues fell short of consensus Wall Street estimates of $175 million.

The company's molecular diagnostic testing revenues decreased 15 percent to $164.5 million from $192.9 in the first quarter of 2014.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers report that deleting one gene from butterflies affects their wing coloration patterns, according to the Washington Post.

The Seattle Times writes that pharmacogenomics testing can help choose medications that may work best for people with depression.

In PNAS this week: genome sequencing of weevil symbionts, retinoid X receptor deletion in lung cancer metastasis, and more.

Sequencing could help combat foodborne illnesses, according to a blog post by Food and Drug Administration officials.